DGX

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Partnerships with other healthcare leaders are accelerating Quest's growth. AI is making the health insights provider more profitable.

Does Quest Diagnostics (DGX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Quest Diagnostics earns a reiterated buy rating after Q2 earnings beat, upgraded FY guidance, and continued market momentum. DGX benefits from strong macro demand for specialized diagnostic testing, peer-leading ROE, and resilient top-line growth (+10.2% YoY). Upward earnings revisions, robust dividend growth, and investment-grade credit ratings support the bull case, though cost pressures and payor risk warrant monitoring.

Quest Diagnostics NYSE: DGX reported double-digit revenue growth and raised its full-year 2026 outlook after what executives described as strong demand across its physician, hospital and consumer channels, as well as increased volume from major collaborations with Corewell Health and Fresenius Medical Care.

Quest Diagnostics Incorporated (DGX) Q2 2026 Earnings Call Transcript

Quest Diagnostics shares rise as second-quarter earnings and revenues beat estimates, testing demand surges and the company raises its 2026 outlook.

Quest Diagnostics (DGX) came out with quarterly earnings of $3.12 per share, beating the Zacks Consensus Estimate of $2.81 per share. This compares to earnings of $2.62 per share a year ago.